Suraksha Diagnostic Q2 PAT Up 69% YoY

Financial Performance Summary

Suraksha Diagnostic Limited reported unaudited financial results for Q2 FY27 and H1 FY27 ended September 30, 2026, with a subsequent corrigendum issued to correct operational metrics.

Q2 FY27 Financial Performance (Year-over-Year)

| Particulars | Q2 FY27 | Q2 FY26 | Y-o-Y Growth |

| EBITDA Margin | 36.7% | 31.7% | 500 bps expansion |

| PAT | ₹149.50 million | ₹88.28 million | 69% |

| PAT Margin | 15.1% | 11.2% | 390 bps expansion |

H1 FY27 Financial Performance (Year-over-Year)

| Particulars | H1 FY27 | H1 FY26 | Y-o-Y Growth |

| EBITDA Margin | 36.3% | 32.8% | 350 bps expansion |

| PAT | ₹277.96 million | ₹180.03 million | 54% |

| PAT Margin | 14.9% | 11.9% | 300 bps expansion |

Corrected Operational Highlights

The company issued a corrigendum to correct the following operational metrics from the original November 10, 2026 release:

Q2 FY27 Operational Metrics (Corrected):

Total tests: 2.40 million (previously reported as 2.32 million)
Tests per patient: 5.70 (previously reported as 0.42)
Average Revenue per test: ₹412 (previously reported as ₹427)

H1 FY27 Operational Metrics (Corrected):

Total tests: 4.50 million (previously reported as 4.42 million)
Tests per patient: 5.63 (previously reported as 0.80)
Average Revenue per test: ₹415 (previously reported as ₹422)

Final Operational Metrics (After Correction)

| Particulars | Q2 FY27 | Q2 FY26 | Y-o-Y | H1 FY27 | H1 FY26 | Y-o-Y |

| Total tests (# million) | 2.40 | 2.20 | 9% | 4.50 | 4.13 | 9% |

| Total Patients (# million) | 0.42 | 0.38 | 12% | 0.80 | 0.71 | 12% |

| Tests per patient (#) | 5.70 | 5.83 | (2%) | 5.63 | 5.78 | (3%) |

| Average Revenue per test (₹) | 412 | 357 | 15% | 415 | 367 | 13% |

| Average Revenue per patient (₹) | 2,348 | 2,083 | 13% | 2,335 | 2,120 | 10% |

Management Commentary

Ms. Ritu Mittal, Joint Managing Director & CEO, commented: \"Suraksha continued its strong growth momentum in Q2 FY27, delivering healthy growth across the business. The performance during the quarter was supported by sustained growth in patient and test volumes, alongside improving contributions from centres commissioned over the past few quarters, which are progressively maturing and contributing to the overall growth.\"

Expansion and Network Development

The company opened five new centres during Q2 FY27, comprising two large centres and three smaller centres, in line with their strategy of building clusters and increasing density around them. This expansion further strengthened their presence across West Bengal while laying groundwork for expansion into newer markets.

Genomics Business Update

Suraksha Genomics continued to focus on building its presence and strengthening its growth trajectory. While still at an early stage, management believes genomics has the potential to emerge as an increasingly meaningful contributor to the business over the coming years.

Outlook

The company remains focused on driving sustainable growth through its existing network, improving the contribution of maturing centres, and pursuing disciplined expansion across newer markets in the second half of FY27.

Company Background

Suraksha Diagnostic Limited is the largest integrated diagnostic chain in East India with presence in West Bengal, Bihar, Assam and Jharkhand. The company provides integrated solutions in pathology and radiology testing, as well as medical consultation services. The central reference laboratory is accredited by the College of American Pathologists, while 4 laboratories hold NABL accreditation, and 6 advanced diagnostic centres are accredited by NABH.

Investor Relations Contact

MUFG Intime India Private Limited

Mr. Omkar Bagwe: omkar.bagwe@in.mpms.mufg.com
Sumeet Khaitan: sumeet.khaitan@in.mpms.mufg.com